Positioning political buying, disclosed 2026-09-17
Options put/call open interest 0.86, read 2026-11-01
Ethical passes the values gate
Price174.87 USD
Fair value166.52
Ethical score81.0/100
RatingQUALITY, FULLY VALUED
Our investment reviews on this name
2026-10-25Read Accumulation175.55-0.4% to today Markup gives way to Accumulation after a 10% rise in 9 weeks
2026-08-26Read Markup159.00+10.0% to today ✓Accumulation gives way to Markup after a 13% rise in 7 days
2026-08-19Read Accumulation141.11+23.9% to today ✓Distribution gives way to Accumulation
2026-07-02Read Distribution135.44+29.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Agilent Technologies holds its Accumulation at $174.87. The statistical read favours the sellers, held for 88 days.
As held on the ledger · 2026-10-30
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 88 days
Price at the screen
$174.87
Valuation
34.49 trailing · 25.99 forward price to earnings
Values screen
PASS· score 81.0
Beta
1.21
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
26.35%
Below 33%
Interest-bearing debt is just 26.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.05%
Below 33%
Cash held in interest-bearing accounts and securities is 1.0% of assets, under the one-third limit.
Pass
Receivables
25.74%
Below 49%
Money owed to the company is 25.7% of assets, under the 49% limit.
Pass
Revenue purity
0.89%
Below 5%
Only 0.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Agilent Technologies clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when A's ethical verdict changes
Today A passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads QUALITY, FULLY VALUED: it trades above our $166.52 fair value estimate, moderate competitive moat, 8.10% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. The price runs 4.8% above the base estimate.
Third-party analyst targets: 20 covering, consensus Buy. The average target sits +6% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $166.52, with a range of $139.50 to $191.50, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Steady lab tools business priced for perfection
Labs that test drugs, food and water need precise instruments that keep working day after day. Agilent supplies those tools across life sciences and diagnostics, delivering 10% revenue growth, 20% profit margins and 21% ROE behind a moderate moat. The numbers look solid and the ethical screen clears it.
Yet the shares trade at 19.9 times forward earnings with our fair value 16% above the current price, leaving no margin of safety. Analysts like the story and push a 159 median target, but that simply bakes in already optimistic growth without room for slippage.
The real risk sits in valuation. Any slowdown in pharma spending or a shift in research budgets could compress multiples quickly, turning a fair business into a trap. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
A trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Accumulation$174.87-0.4%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161.
2026-10-18Markup$175.55+0.2%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161.
2026-10-11Markup$175.21+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161.
2026-10-02Markup$175.21+10.2%Entry 14
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161. Since the last review it its composite score eased.
2026-08-26Markup · changed$159.00+0.0%Entry 13
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Accumulation$159.00+0.0%Entry 12
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Accumulation$159.00+0.0%Entry 11
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Accumulation$159.00+0.0%Entry 10
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Accumulation$159.00+12.7%Entry 9
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it buy, with a mean price target of $161. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
